Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.61 |
| ▸ | HCAR3 | P49019 | 8/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | MAX | P61244 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7436975 | 0.94 | HCAR3 (0.61) | CASP6HCAR3TSHRLMNATTR | |
| SCHEMBL16097751 | 0.88 | CASP6 (0.61) | CASP6HCAR3TSHRLMNATTR | |
| SCHEMBL29189597 | 0.87 | CASP6 (0.56) | CASP6HCAR3TSHRLMNATTR | |
| SCHEMBL3798842 | 0.87 | CASP6 (0.52) | CASP6HCAR3TSHR | |
| SCHEMBL30138067 | 0.85 | HPGD (0.53) | HCAR3LMNAPDE5AMAPT | |
| SCHEMBL23929990 | 0.85 | HPGD (0.53) | HCAR3LMNAPDE5AMAPT | |
| SCHEMBL25292716 | 0.82 | HCAR3 (0.60) | CASP6HCAR3TSHRLMNATTR | |
| SCHEMBL25484985 | 0.81 | PDE5A (0.43) | CASP6HCAR3LMNAPDE5AMAPT | |
| SCHEMBL27639772 | 0.81 | MAPK1 (0.54) | CASP6HCAR3PDE5A | |
| SCHEMBL7353109 | 0.81 | PDE5A (0.50) | HCAR3LMNAPDE5AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2021214136-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572367-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | CASP6 1376/4885HCAR3 118/4885TSHR 3778/4885 |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | CASP6 1376/4885HCAR3 118/4885TSHR 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.